Bristol-Myers Squibb, Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar's CD122-biased Agonist, NKTR-214; Nektar To Pay $1.85B Upfront Comprised Of $1B In Cash & Purchase Of 8.28M Shares At $102.60/Share